Helpful resources to support treatment with KLISYRI®
SEE PRESCRIBER SUPPORT MATERIALSResources for you
Educational materials
Prior Authorization Support Guide
Designed to simplify the medication
access challenges for you and your
office staff with an easy-to-follow guide
to completing the PA request process.
Access & Affordability Guide
Get helpful information to help your
patients save on their KLISYRI®
prescription.
Videos
KLISYRI® Treatment Testimonial Videos
Hear from four real-world physicians who share their experiences prescribing KLISYRI® for their patients with actinic keratosis.
Stephen Tyring, MD, PhD,
board-certified dermatologist
Hear why Houston-based dermatologist Dr Stephen Tyring started prescribing KLISYRI® after participating in the clinical trials
Tricia Brown, MD, FAAD,
board-certified dermatologist
Learn why board-certified dermatologist Dr Tricia Brown was so excited about KLISYRI®
Mike Stierstorfer, MD, FAAD,
board-certified dermatologist
Find out why this Philadelphia-based dermatologist started prescribing field therapy with KLISYRI®
Mike Stierstorfer, MD, FAAD,
board-certified dermatologist
Find out why this Philadelphia-based dermatologist started prescribing field therapy with KLISYRI®
Tricia Brown, MD, FAAD,
board-certified dermatologist
Learn why board-certified dermatologist Dr Tricia Brown was so excited about KLISYRI®
Kimberly Boldon, APRN, nurse
practitioner
Listen to what NP Kimberly Boldon’s patients said about using KLISYRI®
Patient Profile
Video
Learn why KLISYRI® is a modern AK treatment option for cosmetically conscious patients with actinic keratosis.
Meet Kaitlyn...
Hear why patients may benefit from a modern, 5-day AK treatment
Microtubule
Inhibition Video
See microtubule inhibition in action
KLISYRI® is a microtubule inhibitor
LEARN ABOUT PATIENT ACCESS AND SAVINGS
IMPORTANT SAFETY INFORMATION
INDICATION
KLISYRI is a microtubule inhibitor indicated for the topical field treatment of actinic keratosis on the face or scalp.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Ophthalmic Adverse Reactions
KLISYRI may cause eye irritation. Avoid transfer of the drug into the eyes and to the periocular area during and after application. Wash hands immediately after application. If accidental exposure occurs, instruct patient to flush eyes with water and seek medical care as soon as possible.
Local Skin Reactions
Local skin reactions, including severe reactions (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) in the treated area can occur after topical application of KLISYRI. Occlusion after topical application of KLISYRI is more likely to result in irritation. Avoid use until skin is healed from any previous drug, procedure, or surgical treatment.
ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2%) were local skin reactions, application site pruritus, and application site pain.
Please see full Prescribing Information.
To report an adverse event or product complaint, call or email Medical Affairs and Customer Relations • Phone: 1-866-665-2782• Fax: 510-595-8183 •
Email: almirallmc@eversana.com